To access this element change to forms mode OFF
Grant Award View - GA85467
Monoclonal antibody therapy of COVID-19
GA ID:
GA85467
Agency:
Department of Health and Aged Care
Approval Date:
29-May-2020
Publish Date:
23-Jun-2020
Category:
Health and Medical Research
Grant Term:
1-Jun-2020 to 31-May-2021
Value (AUD):
$594,420.08
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 19/20 1.1 Health Policy Research and Analysis
Grant Program:
2020_MRFF_Anti_Viral_COVID19
Grant Activity:
Monoclonal antibody therapy of COVID-19
Purpose:
The 2019/20 coronavirus (COVID-19) outbreak originating in the Wuhan province of China represents a major health emergency. In the earlier 2003 outbreak protective antibodies against the highly related SARS coronavirus have been described. Intriguingly, recent data indicate that these antibodies may not only be applicable to SARS, but also to COVID-19. Here we outline a strategy to develop these antibodies for COVID-19 therapy.
GO ID:
GO Title:
MRFF – 2020 Antiviral Development for COVID-19 Grant Opportunity
Internal Reference ID:
MRF2001739
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
Garvan Institute of Medical Research
Recipient ABN:
62 330 391 937
Grant Recipient Location
Suburb:
Darlinghurst
Town/City:
Darlinghurst
Postcode:
2010
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW
Postcode:
Country:
AUSTRALIA